Lupeol triterpene, a novel diet-based microtubule targeting agent: Disrupts survivin/cFLIP activation in prostate cancer cells

Biochemical and Biophysical Research Communications

Volumn 388, Issue 3, 2009, Pages 576-582

  Saleem, Mohammad ^a   Murtaza, Imtiyaz ^a   Witkowsky, Olya ^a   Kohl, Amanda Marie ^a   Maddodi, Nityanand ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

cFLIP; G2 M arrest; Lupeol; Microtubule; Prostate cancer; Stathmin; Survivin

Indexed keywords

ALPHA TUBULIN; BETA TUBULIN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYCLIN E2; FLICE INHIBITORY PROTEIN; LUPEOL; STATHMIN; SURVIVIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; PRIORITY JOURNAL; PROSTATE CANCER;

ANIMALS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DIET; HUMANS; MALE; MICE; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; PENTACYCLIC TRITERPENES; PROSTATIC NEOPLASMS; TRANSCRIPTIONAL ACTIVATION; TRITERPENES; TUBULIN MODULATORS;

EID: 69549111679     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.08.060     Document Type: Article

References (25)

1. Syed D.N., Khan N., Afaq F., and Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2193-2203
2. Bradford P.G., and Awad A.B. Phytosterols as anticancer compounds. Mol. Nutr. Food Res. 51 (2007) 161-170
3. Beveridge T.H., Li T.S., and Drover J.C. Phytosterol content in American ginseng seed oil. J. Agric. Food Chem. 50 (2002) 744-750
4. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett. (2009) (Epub ahead of print)
5. Saleem M., Alam A., Arifin S., Shah M.S., Ahmed B., and Sultana S. Lupeol, a triterpene, inhibits early responses of tumor promotion induced by benzoyl peroxide in murine skin. Pharmacol. Res. 43 (2001) 127-134
6. Murtaza I., Saleem M., Adhami V.M., Hafeez B.B., and Mukhtar H. Suppression of cFLIP by Lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells. Cancer Res. 69 (2009) 1156-1165
7. Saleem M., Maddodi N., Abu Zaid M., Khan N., Hafeez B.B., Asim M., Suh Y., Yun J.M., Setaluri V., and Mukhtar H. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res. 14 (2008) 2119-2127
8. Lee T.K., Poon R.T., Wo J.Y., Ma S., Guan X.Y., Myers J.N., Altevogt P., and Yuen A.P. Lupeol suppresses cisplatin-induced nuclear factor-kappa B activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model. Cancer Res. 67 (2007) 8800-8809
9. Saleem M., Kweon M.H., Yun J.M., Adhami V.M., Khan N., Syed D.N., and Mukhtar H. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model. Cancer Res. 65 (2005) 11203-11213
10. Revelos K., Petraki C., Scorilas A., Stefanakis S., Malovrouvas D., Alevizopoulos N., Kanellis G., Halapas A., and Koutsilieris M. Correlation of androgen receptor status, neuroendocrine differentiation and angiogenesis with time-to-biochemical failure after radical prostatectomy in clinically localized prostate cancer. Anticancer Res. 27 (2007) 651-660
11. Scholey J.M., Brust-Mascher I., and Mogilner A. Cell division. Nature 422 (2003) 746-752
12. DiPaola R.S. To arrest or not to G [2]-M cell-cycle arrest. Clin. Cancer Res. 8 (2002) 3512-3519
13. Buolamwini J.K. Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des. 6 (2000) 379-392
14. Malumbres M., and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9 (2009) 53-166
15. Zhu H., Fang K., and Fang G. Mechanism, function and regulation of microtubule-dependent microtubule amplification in mitosis. Mol. Cells 27 (2009) 1-3
16. Bhalla K.N. Microtubule-targeted anticancer agents and apoptosis. Oncogene 22 (2003) 9075-9086
17. Islam M.N., and Iskander M.N. Microtubulin binding sites as target for developing anticancer agents. Mini Rev. Med. Chem. 4 (2004) 1077-1104
18. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist. Updat. 4 (2001) 3-8
19. Gavet O., Ozon S., Manceau V., Lawler S., Curmi P., and Sobel A. The stathmin phosphoprotein family: intracellular localization and effects on the microtubule network. J. Cell Sci. 111 (1998) 3333-3346
20. Rana S., Maples P.B., Senzer N., and Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev. Anticancer Ther. 8 (2008) 1461-1470
21. Yamamoto H., Ngan C.Y., and Monden M. Cancer cells survive with survivin. Cancer Sci. 99 (2008) 1709-1714
22. Mita A.C., Mita M.M., Nawrocki S.T., and Giles F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 4 (2008) 5000-5005
23. Ghavami S., Hashemi M., Ande S.R., Yeganeh B., Xiao W., Eshraghi M., Bus C.J., Kadkhoda K., Wiechec E., Halayko A.J., and Los M. Apoptosis and cancer: mutations within caspase genes. J. Med. Genet. 46 (2009) 497-510
24. Kataoka T. The caspase-8 modulator c-FLIP. Crit. Rev. Immunol. 25 (2005) 31-58
25. Wajant H. Targeting the FLICE inhibitory protein (FLIP) in cancer therapy. Mol. Interv. 3 (2003) 124-127